Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers

• US 4,361,544 A
• Filed: 03/03/1980
• Issued: 11/30/1982
• Est. Priority Date: 03/03/1980
• Status: Expired due to Term

• Current Assignee: Milton D., Lexington Goldenberg
• Original Assignee: Milton D., Lexington Goldenberg
• Inventors: Goldenberg, Milton D.
• Primary Examiner(s): Nucker, Christine M.
• Application Number:
  US06/126,261
• Time in Patent Office: 1,002 Days
• Field of Search: 424/1, 424/9
• US Class Current: 424/1.49
• CPC Class Codes: A61K 2121/00 Preparations for use in therapy
• CPC Class Codes: A61K 2123/00 Preparations for testing in vivo
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 51/1048 the tumor cell determinant being a carcino embryonic antigen
• CPC Class Codes: C07K 16/3007 Carcino-embryonic Antigens

Abstract

Methods are provided for using radiolabeled antibodies specific to intracellular tumor-associated markers for detection, locatization and therapy of tumors. Antibodies and injectable compositions for use in the methods of the invention are also provided.

Claims

1. A method for detecting and localizing a tumor which either produces or is associated with an intracellular marker substance, which comprises injecting a human subject parenterally with an antibody specific to said marker substance and radiolabeled with a pharmacologically inert radioisotope capable of detection using a photoscanning device, and normal immunoglobulin from the same or different species as that used to prepare said specific antibody, said normal immunoglobulin being radio-labeled with a different isotope of the same element used to label the specific antibody, said different isotope emitting at a different energy from the marker-specific antibody label and being capable of independent detection by said photoscanning device;

and subsequently scanning with said device, the level of activity of said normal immunoglobulin being used to determine the background activity due to non-targeted specific antibody, said background activity being subtracted from the total activity of the specific antibody, whereby the activity of substantially only the targeted, tumor-associated antibody is determined, and thereby detecting and localizing the site or sites of uptake of said labeled antibody by said tumor.

2. The method of claim 1, wherein said marker-specific antibody is a substantially monospecific antibody having a marker-specific immunoreactivity prior to labeling of at least 70% and a cross-reactivity to non-tumor-associated antigens of less than 15%.

3. The method of claim 2, wherein said substantially monospecific antibody is a monoclonal antibody.

4. The method of claim 2, wherein said antibody is radiolabeled to an extent sufficient to reduce its marker-specific immunoreactivity by from 5 to 33%.

5. The method of claim 4, wherein said substantially monospecific antibody is radiolabeled with Iodine-131 or Iodine-123, an average of at least 5 atoms of iodine per antibody molecule being introduced by direct substitution of iodine for hydrogen on the antibody molecule.

6. The method of claim 1, wherein said marker substance is an oncofetal antigen.

7. The method of claim 1, wherein said marker substance is a placental antigen.

8. The method of claim 1, wherein said marker substance is an oncogenic or tumor virus associated antigen.

9. The method of claim 1, wherein said marker substance is a tissue- or organ-associated antigen, an ectopic hormone or a normal antigen or variant thereof.

10. The method of claim 1, wherein said marker substance is alpha-fetoprotein (AFP).

11. The method of claim 1, wherein said marker substance is human chorionic gonadotropin (HCG) or its beta-subunit.

12. The method of claim 1, wherein said marker substance is colon-specific antigen-p (CSAp).

13. The method of claim 1, wherein said marker substance is one of prostatic acid phosphatase, pancreatic oncofetal antigen, placental alkaline phosphatase, pregnancy beta₁ -globulin, parathromone, calcitonin, tissue polypeptide antigen, T-antigen, beta₂ -microglobulin, transferase-II (GT-II), gp-52 viral-associated antigen, ovarian cystadenocarcinoma-associated antigen (OCAA), ovarian tumor-specific antigen (OCA), cervical cancer antigens (CA-58, CCA, TA-4), basic fetoprotein (BFP), terminal deoxynucleotidyl transferase (TdT), cytoplasmic melanoma-associated antigens, human astrocytoma-associated antigen (HAAA), common glioma antigen (CGA), glioembryonic antigen (GEA), glial fibrillary acidic protein (GFA), common meningioma antigen (CMA) and tumor angiogenesis factor (TAF).

14. The method of claim 1, wherein said radiolabeled normal immunoglobulin is injected concurrently with said radiolabeled marker-specific antibody.

15. The method of claim 1, wherein the specific antibody is labeled with one of a pair of radioisotopes and the normal immunoglobulin is labeled with the other of the pair, said pair being one of Iodine-131 and Iodine-123;

Indium-111 and Indium-113m;

Gallium-67 and Gallium-68;

Ruthenium-97 and Ruthenium-103;

or Mercury-197 and Mercury-203.

16. An injectable composition, which comprises

(a) a substantially monospecific antibody having a specific immunoreactivity of at least 70% to an intracellular marker substance produced by or associated with a tumor and a cross-reactivity to non-tumor associated antigens of less than 15%;

said antibody being radiolabeled with one of Iodine-131 and Iodine-123 by direct substitution of iodine for hydrogen on the antibody molecule to an extent sufficient to reduce its specific immunoreactivity by from 5 to 33%;

(b) normal immunoglobulin from the same or different species as that used to prepare said specific antibody, said normal immunoglobulin being radiolabeled with the other of Iodine-131 and Iodine-123 by direct substitution of iodine for hydrogen on the immunoglobulin molecule; and

(c) a pharmaceutically acceptable injection vehicle.

17. The composition of claim 16, wherein said monospecific antibody is a monoclonal antibody.

18. The composition of claim 17, wherein said monoclonal antibody is raised in a monkey, and antibody-producing monkey lymph or spleen cells are fused with human or mouse myeloma cells to produce hybrid cells which are isolated, cloned and selected for their ability to produce monoclonal antibodies specific to said marker substance.

19. The composition of claim 16, wherein said marker substance is one of AFP, HCG and CSAp.

20. The composition of claim 16, wherein said marker substance is one of prostatic acid phosphatase, pancreatic oncofetal antigen, placental alkaline phosphatase, pregnancy beta₁ -globulin, parathormone, calcitonin, tissue polypeptide antigen, T-antigen, beta₂ -microglobulin, galactyosyl transferase-II (GT-II), gp-52 viral-associated antigen, ovarian cystadenocarcinoma-associated antigen (OCAA), ovarian tumor-specific antigen (OCA), cervical cancer antigens (CA-58, CCA, TA-4), basic fetoprotein (BFP), terminal deoxynucleotic transferase (TdT), cytoplasmic melanoma-associated antigens, human astrocytoma-associated antigen (HAAA), common glioma antigen (CGA), glioembryonic antigen (GEA), glial fibrillary acidic protein (GFA), common meningioma antigen (CMA) and tumor angiogenesis factor (TAF).

21. An antibody which is specific to an intracellular marker substance produced by or associated with a tumor, said antibody being radiolabeled with a pharmacologically inert radioisotope capable of detection with a photoscanning device, said labeled antibody further containing in chemical combination at least one addend containing at least five atoms of boron with at least a natural abundance of Boron-10 isotope.

22. An injectable composition, which comprises

(a) an antibody which is specific to an intracellular marker substance produced by or associated with a tumor, said antibody being radio-labeled with a pharmacologically inert radioisotope capable of detection with a photoscanning device, said labeled antibody further containing in chemical combination at least one addend containing at least five atoms of boron with at least a natural abundance of Boron-10 isotope;

and

(b) a pharmaceutically acceptable injection vehicle.

23. The injectable composition of claim 22, which further comprises normal immunoglobulin from the same or different species as that used to prepare said specific antibody, said normal immunoglobulin being radiolabeled with a different isotope of the same element used to label the specific antibody and emitting at an energy capable of independent detection using said photoscanning device.

24. A method of tumor radiotherapy, which comprises parenterally injecting into a human subject having a tumor which produces or is associated with an intracellular marker substance an effective tumor reducing amount of an antibody which is specific to said marker substance and radiolabeled with a pharmacologically inert, radiotherapeutically effective radioisotope.

25. The method of claim 24, wherein said radioisotope is I-131 and said amount is from 25 to 250 mCi per administration.

26. A method of tumor radiotherapy, which comprises parenterally injecting into a human subject having a tumor which produces or is associated with an intracellular marker substance a radiotherapeutically effective amount of an antibody which is specific to said marker substance and radiolabeled with a pharmacologically inert radioisotope capable of detection with a photo-scanning device, said labeled antibody further containing in chemical combination at least one addend containing at least five atoms of boron with at least a natural abundance of Boron-10 isotope;

wherein the location of said tumor is determined using said photoscanning device, and a beam of thermal neutrons is then directed at said tumor location.